Skip to content
DraconiticResearch
Search Sources API
197,788 studies31 sourcesUpdated 19 min ago
Peer-reviewedCC BY-NC-NDCancer innovation

Dual PD-1/LAG-3 Blockade in Breast Cancer: Navigating Benefit and Risk.

  • Kaixiang Feng1
  • Fanxiang Yin1
  • Mengting Chen2
  • Zongbi Yi3
  1. 1Translational Medical Center The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan China.
  2. 2School of Biological Sciences University of Southampton Southampton Hampshire UK.
  3. 3National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Shenzhen Guangdong China.
Read full textPDFDOICite

Related

  1. IL-6R blockade with tocilizumab disrupts pericyte– and tumor cell–driven IL-6/STAT3 signaling, enhancing docetaxel efficacy in ER+ breast cancer
    Róża K. Przanowska, Jacky Gomez-Villa, Victoria J. Liu +5
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textOncologyCrossref
  2. Site-specific immune remodeling underlies resistance to dual immune checkpoint blockade in metastatic colorectal cancer
    I. Baraibar, S. Morabito, G. Deuner-Cos +25
    medRxivPreprintAll rights reservedFull textOncologymedRxiv
  3. A therapeutic vulnerability linking MNK1/2 inhibition and G1/S cyclin-dependent kinase blockade in triple-negative breast cancer
    Q. Deng, M. Amiri, A. Moshari +11
    bioRxivPreprintCC BYFull textOncologybioRxiv
  4. A tumor-responsive nanoplatform orchestrating multiplexed macrophage engagers and immune checkpoint blockade for triple-negative breast cancer immunotherapy
    Bo Xiang, Tao Liu, Wei Wang +3
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Pharmacology & toxicologyCrossref
  5. Safety-guided selection of CDK4/6 inhibitors in HR+/HER2− metastatic breast cancer: toxicity profiles, dose modification, and clinical risk–benefit considerations
    Nidhi Shrivastava, Santosh Laxman Gaonkar, Fayaz Shaik Mahammad
    Therapeutic Advances in Drug SafetyPeer-reviewedCC BY-NC 4.0Full textGeneral medicinePMCEurope PMC

Cite

BibTeXRIS
BibTeX
@article{feng2026dual,
  title = {{Dual PD-1/LAG-3 Blockade in Breast Cancer: Navigating Benefit and Risk.}},
  author = {Kaixiang Feng and Fanxiang Yin and Mengting Chen and Zongbi Yi},
  journal = {Cancer innovation},
  year = {2026},
  month = oct,
  doi = {10.1002/cai2.70088},
  url = {https://europepmc.org/article/MED/42947999},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Dual PD-1/LAG-3 Blockade in Breast Cancer: Navigating Benefit and Risk.
AU  - Kaixiang Feng
AU  - Fanxiang Yin
AU  - Mengting Chen
AU  - Zongbi Yi
PY  - 2026
DA  - 2026/10/27
JO  - Cancer innovation
DO  - 10.1002/cai2.70088
UR  - https://europepmc.org/article/MED/42947999
SN  - 2770-9191
SN  - 2770-9183
ER  -